A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

NCT03597581 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

89

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastrointestinal Cancer
Gastrointestinal Neoplasms
Colorectal Cancer
Colorectal Neoplasms
Colorectal Carcinoma
Gastric Cancer
Gastric Neoplasm
KRAS Mutation-Related Tumors
CRC
Colorectal Cancer Metastatic

Interventions

DRUG: ompenaclid
DRUG: FOLFIRI
DRUG: Bevacizumab
DRUG: FOLFOX regimen

Sponsor

Inspirna, Inc.